| Jill Rubinstein, | |
|
2800 Main St, Bridgeport, CT 06606-4292 | |
| (203) 576-6000 | |
| Not Available |
| Full Name | Jill Rubinstein |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 12 Years |
| Location | 2800 Main St, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477810992 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086X0206X | Surgery - Surgical Oncology | 66447 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Vincent's Medical Center | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.
Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.
A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
› Verified 1 days ago
| Entity Name | St. Vincent's Multispecialty Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043544489 PECOS PAC ID: 6204977218 Enrollment ID: O20100112000538 |
News Archive
A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.
Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.
A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
› Verified 1 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.
Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.
A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jill Rubinstein, 2800 Main St, Bridgeport, CT 06606-4292 Ph: () - | Jill Rubinstein, 2800 Main St, Bridgeport, CT 06606-4292 Ph: (203) 576-6000 |
News Archive
A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.
Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.
A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
› Verified 1 days ago
Dr. Jitendra Bhagwandas Bharucha, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 2660 Main St, Suite 110, Bridgeport, CT 06606 Phone: 203-332-4744 Fax: 203-333-4751 | |
Dr. Vincent A Manjoney Jr., MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2720 Main St, 3rd Floor South, Bridgeport, CT 06606 Phone: 203-579-7500 Fax: 203-576-0035 | |
Andrew S Kenler, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610 Phone: 203-384-3873 Fax: 203-384-3829 | |
William R Butler, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610 Phone: 203-384-3873 Fax: 203-384-3829 | |
Dr. Felix B Mpuku, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3180 Main St, Suite 305, Bridgeport, CT 06606 Phone: 203-372-6322 Fax: 203-371-8930 | |
Alisa Savetamal, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610 Phone: 203-384-3873 Fax: 203-384-3829 | |
Eric Tsung, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-3000 |